ELITE PHARMACEUTICALS INC /NV/
Qualité des données : 100%
ELTP
OTC
Manufacturing
Chemicals
0,38 €
0,00 €
(0,00%)
6 months return
—
Momentum
Neutral
5Y revenue growth
34,90%
Croissance
Revenue Growth (5Y)
34,90%
Au-dessus de la moyenne du secteur (1,82%)
Revenue (1Y)48,42%
Earnings (1Y)-121,46%
FCF Growth (3Y)N/A
Qualité
Return on Equity
61,18%
Au-dessus de la moyenne du secteur (-54,47%)
ROIC35,81%
Net Margin30,98%
Op. Margin35,74%
Sécurité
Debt / Equity
N/A
Current Ratio7,34
Interest Coverage440,71
Valorisation
PE (TTM)
9,43
Au-dessus de la moyenne du secteur (-1,49)
P/B Ratio5,10
EV/EBITDA7,99
Dividend YieldN/A
Quick Summary
Key Takeaways
Short bullets derived from reported financials—not the AI summary above.
Revenue grew 34,90% annually over 5 years — strong growth
Earnings declined -121,46% over the past year
ROE of 61,18% indicates high profitability
Net margin of 30,98% shows strong profitability
Generating 17,24 M in free cash flow
P/E of 9,43 — trading at a low valuation
Price History
Tendances Financières
Objectif de Cours des Analystes
Aucune couverture d'analyste disponible
Surprises de Résultats
EPS
Reported
Estimate
| Q22010 | Q32010 | Q42010 | |
|---|---|---|---|
| Reported | -0,05 € | 0,01 € | 0,02 € |
| Estimate | — | — | — |
| Surprise | — | — | — |
Growth
Rev 5Y: 34,90% · Earnings 1Y: -121,46%
Growth
Rev 5Y: 34,90% · Earnings 1Y: -121,46%| Revenue Growth (1Y) | 48,42% | Revenue Growth (3Y) | 56,86% |
| Earnings Growth (1Y) | -121,46% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 34,90% | Earnings Growth (5Y) | N/A |
Profitability
ROE: 61,18% · Net Margin: 30,98%
Profitability
ROE: 61,18% · Net Margin: 30,98%| Revenue (TTM) | 140,12 M | Net Income (TTM) | 43,41 M |
| ROE | 61,18% | ROA | 35,63% |
| Gross Margin | 51,06% | Operating Margin | 35,74% |
| Net Margin | 30,98% | Free Cash Flow (TTM) | 17,24 M |
| ROIC | 35,81% | FCF Growth (3Y) | N/A |
Safety
D/E: N/A · Current: 7,34
Safety
D/E: N/A · Current: 7,34| Debt / Equity | N/A | Current Ratio | 7,34 |
| Interest Coverage | 440,71 | Asset Turnover | 1,15 |
| Working Capital | 83,60 M | Tangible Book Value | 74,68 M |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: 9,43 · EV/EBITDA: 7,99
Valuation
P/E: 9,43 · EV/EBITDA: 7,99| P/E Ratio | 9,43 | Forward P/E | N/A |
| P/B Ratio | 5,10 | P/S Ratio | 2,92 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | 7,99 | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | 4,21% | ||
| Market Cap | 409,26 M | Enterprise Value | 409,26 M |
Per Share
EPS: 0,04 · FCF/Share: 0,02
Per Share
EPS: 0,04 · FCF/Share: 0,02| EPS (Diluted TTM) | 0,04 | Revenue / Share | 0,13 |
| FCF / Share | 0,02 | OCF / Share | 0,02 |
| EPS CAGR (1Y) | -100,00% | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: 39,71% · CapEx/Rev: 0,91%
Efficiency
FCF Conv: 39,71% · CapEx/Rev: 0,91%| CapEx / Revenue | 0,91% | FCF Conversion | 39,71% |
| SBC-Adj. FCF | N/A | Growth Momentum | 13,52 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 84,04 M | 56,63 M | 34,16 M | 32,26 M | 25,38 M |
| Net Income | -4,31 M | 20,11 M | 3,56 M | 8,90 M | 5,09 M |
| EPS (Diluted) | 0,00 | 0,02 | 0,00 | 0,01 | 0,01 |
| Gross Profit | 40,09 M | 26,36 M | 16,59 M | 14,80 M | 11,87 M |
| Operating Income | 19,60 M | 10,79 M | 3,68 M | 5,07 M | 2,10 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 7,96 M | 6,88 M | 6,20 M | 4,05 M | 5,11 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 1,23 M | 1,32 M | 1,28 M | 1,21 M | 1,31 M |
| Interest Expense | 128 234,0 | 588 622,0 | 1,11 M | 191 816,0 | 259 598,0 |
| Income Tax | 4,26 M | -19,65 M | 424 028,0 | -1,74 M | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 96,39 M | 83,65 M | 40,90 M | 35,15 M | 26,19 M |
| Total Liabilities | 42,87 M | 26,07 M | 11,94 M | 9,93 M | 10,04 M |
| Shareholders' Equity | 53,52 M | 57,58 M | 28,96 M | 25,22 M | 16,15 M |
| Total Debt | — | — | — | 1,36 M | 1,47 M |
| Cash & Equivalents | — | 7,11 M | 7,83 M | 8,54 M | 3,19 M |
| Current Assets | 57,74 M | 40,01 M | 21,51 M | 18,86 M | 12,19 M |
| Current Liabilities | 11,84 M | 13,05 M | 7,83 M | 6,69 M | 5,81 M |
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1605 pairs)
Par rapport à des entreprises similaires dans Manufacturing
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1605 pairs) Par rapport à des entreprises similaires dans Manufacturing| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | 9,4 | -1,5 |
| P/B | 5,1 | 1,6 |
| ROE % | 61,2 | -54,5 |
| Net Margin % | 31,0 | -41,5 |
| Rev Growth 5Y % | 34,9 | 1,8 |
| D/E | — | 0,3 |
Scores de Stratégies
1 strategy matched
Scores de Stratégies
1 strategy matched
Growth
Capital Light Compounder
#11 of 85
Activité Récente
Entré
Capital Light Compounder
Apr 12, 2026
{"event":"ticker_viewed","properties":{"ticker":"ELTP","listing_kind":"stock","pathname":"/stocks/eltp","exchange":"OTC","country":"US"}}